S&P 500   4,292.75 (+0.24%)
DOW   33,765.23 (+0.01%)
QQQ   355.20 (+0.16%)
AAPL   183.41 (+1.36%)
MSFT   336.02 (+0.18%)
META   272.09 (-0.19%)
GOOGL   125.06 (+0.31%)
AMZN   124.26 (+0.01%)
TSLA   219.06 (+2.38%)
NVDA   393.30 (+0.01%)
NIO   7.69 (+1.72%)
BABA   84.00 (-0.32%)
AMD   117.25 (-0.52%)
T   15.32 (+0.72%)
F   12.64 (+2.02%)
MU   68.75 (-0.61%)
CGC   0.82 (-0.32%)
GE   105.34 (-0.43%)
DIS   90.42 (-0.39%)
AMC   4.63 (+1.76%)
PFE   38.51 (+0.39%)
PYPL   64.35 (+0.61%)
NFLX   402.81 (+0.58%)
S&P 500   4,292.75 (+0.24%)
DOW   33,765.23 (+0.01%)
QQQ   355.20 (+0.16%)
AAPL   183.41 (+1.36%)
MSFT   336.02 (+0.18%)
META   272.09 (-0.19%)
GOOGL   125.06 (+0.31%)
AMZN   124.26 (+0.01%)
TSLA   219.06 (+2.38%)
NVDA   393.30 (+0.01%)
NIO   7.69 (+1.72%)
BABA   84.00 (-0.32%)
AMD   117.25 (-0.52%)
T   15.32 (+0.72%)
F   12.64 (+2.02%)
MU   68.75 (-0.61%)
CGC   0.82 (-0.32%)
GE   105.34 (-0.43%)
DIS   90.42 (-0.39%)
AMC   4.63 (+1.76%)
PFE   38.51 (+0.39%)
PYPL   64.35 (+0.61%)
NFLX   402.81 (+0.58%)
S&P 500   4,292.75 (+0.24%)
DOW   33,765.23 (+0.01%)
QQQ   355.20 (+0.16%)
AAPL   183.41 (+1.36%)
MSFT   336.02 (+0.18%)
META   272.09 (-0.19%)
GOOGL   125.06 (+0.31%)
AMZN   124.26 (+0.01%)
TSLA   219.06 (+2.38%)
NVDA   393.30 (+0.01%)
NIO   7.69 (+1.72%)
BABA   84.00 (-0.32%)
AMD   117.25 (-0.52%)
T   15.32 (+0.72%)
F   12.64 (+2.02%)
MU   68.75 (-0.61%)
CGC   0.82 (-0.32%)
GE   105.34 (-0.43%)
DIS   90.42 (-0.39%)
AMC   4.63 (+1.76%)
PFE   38.51 (+0.39%)
PYPL   64.35 (+0.61%)
NFLX   402.81 (+0.58%)
S&P 500   4,292.75 (+0.24%)
DOW   33,765.23 (+0.01%)
QQQ   355.20 (+0.16%)
AAPL   183.41 (+1.36%)
MSFT   336.02 (+0.18%)
META   272.09 (-0.19%)
GOOGL   125.06 (+0.31%)
AMZN   124.26 (+0.01%)
TSLA   219.06 (+2.38%)
NVDA   393.30 (+0.01%)
NIO   7.69 (+1.72%)
BABA   84.00 (-0.32%)
AMD   117.25 (-0.52%)
T   15.32 (+0.72%)
F   12.64 (+2.02%)
MU   68.75 (-0.61%)
CGC   0.82 (-0.32%)
GE   105.34 (-0.43%)
DIS   90.42 (-0.39%)
AMC   4.63 (+1.76%)
PFE   38.51 (+0.39%)
PYPL   64.35 (+0.61%)
NFLX   402.81 (+0.58%)
NASDAQ:SERA

Sera Prognostics (SERA) Stock Forecast, Price & News

$3.25
+0.03 (+0.93%)
(As of 09:30 AM ET)
Compare
Today's Range
$3.25
$3.25
50-Day Range
$3.20
$3.90
52-Week Range
$1.10
$4.25
Volume
313 shs
Average Volume
813,035 shs
Market Capitalization
$100.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.25

Sera Prognostics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
92.3% Upside
$6.25 Price Target
Short Interest
Healthy
1.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.38) to ($1.32) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

973rd out of 980 stocks

Medical Laboratories Industry

22nd out of 22 stocks


SERA stock logo

About Sera Prognostics (NASDAQ:SERA) Stock

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Receive SERA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sera Prognostics and its competitors with MarketBeat's FREE daily newsletter.

SERA Stock News Headlines

AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
Recap: Sera Prognostics Q1 Earnings
AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
Sera Prognostics, Inc. (SERA) Reports Q1 Loss
Sera Prognostics A earnings preview: what Wall Street is expecting
See More Headlines

SERA Price History

SERA Company Calendar

Last Earnings
3/22/2023
Today
6/05/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SERA
Fax
N/A
Employees
113
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.25
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+92.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-44,190,000.00
Net Margins
-12,891.82%
Pretax Margin
-12,891.82%

Debt

Sales & Book Value

Annual Sales
$270,000.00
Book Value
$2.91 per share

Miscellaneous

Free Float
26,208,000
Market Cap
$100.91 million
Optionable
Not Optionable
Beta
0.26

Key Executives

  • Dr. Gregory C. Critchfield M.D. (Age 70)
    M.S., Exec. Chairman, CEO & Pres
    Comp: $775.1k
  • Mr. Robert G. Harrison (Age 57)
    Chief Information Officer
    Comp: $384.18k
  • Mr. Benjamin G. Jackson J.D. (Age 43)
    Gen. Counsel
    Comp: $410.75k
  • Dr. Steven W. Graves
    Co-Founder and Co-Chairman of The Scientific Advisory Board
  • Dr. M. Sean Esplin M.D.
    Co-Founder and Co-Chairman of Scientific Advisory Board
  • Mr. Jay M. Moyes M.B.A. (Age 69)
    MBA, Chief Financial Officer
  • Dr. John J. Boniface Ph.D. (Age 60)
    Chief Scientific Officer
  • Ms. Nadia F. Altomare (Age 52)
    Chief Commercial Officer
  • Dr. Paul Kearney Ph.D. (Age 55)
    Chief Data Officer
  • Dr. Michael R. Foley M.D.
    Chief Medical Officer













SERA Stock - Frequently Asked Questions

Should I buy or sell Sera Prognostics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sera Prognostics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SERA shares.
View SERA analyst ratings
or view top-rated stocks.

What is Sera Prognostics' stock price forecast for 2023?

3 Wall Street analysts have issued twelve-month price objectives for Sera Prognostics' stock. Their SERA share price forecasts range from $1.50 to $11.00. On average, they predict the company's stock price to reach $6.25 in the next year. This suggests a possible upside of 92.3% from the stock's current price.
View analysts price targets for SERA
or view top-rated stocks among Wall Street analysts.

How have SERA shares performed in 2023?

Sera Prognostics' stock was trading at $1.26 at the beginning of the year. Since then, SERA shares have increased by 157.9% and is now trading at $3.25.
View the best growth stocks for 2023 here
.

When is Sera Prognostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our SERA earnings forecast
.

How were Sera Prognostics' earnings last quarter?

Sera Prognostics, Inc. (NASDAQ:SERA) announced its earnings results on Wednesday, March, 22nd. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.11. The firm had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.13 million. Sera Prognostics had a negative trailing twelve-month return on equity of 41.18% and a negative net margin of 12,891.82%.

When did Sera Prognostics IPO?

(SERA) raised $75 million in an initial public offering on Thursday, July 15th 2021. The company issued 4,687,500 shares at $15.00-$17.00 per share.

What is Sera Prognostics' stock symbol?

Sera Prognostics trades on the NASDAQ under the ticker symbol "SERA."

Who are Sera Prognostics' major shareholders?

Sera Prognostics' stock is owned by many different retail and institutional investors. Top institutional investors include Baker BROS. Advisors LP (5.77%), Sanders Morris Harris LLC (1.41%), Geode Capital Management LLC (0.47%), Riverview Capital Advisers LLC (0.33%), Requisite Capital Management LLC (0.18%) and State Street Corp (0.16%). Insiders that own company stock include Benjamin Jackson and John J Boniface.
View institutional ownership trends
.

How do I buy shares of Sera Prognostics?

Shares of SERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sera Prognostics' stock price today?

One share of SERA stock can currently be purchased for approximately $3.25.

How much money does Sera Prognostics make?

Sera Prognostics (NASDAQ:SERA) has a market capitalization of $100.91 million and generates $270,000.00 in revenue each year. The company earns $-44,190,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis.

How many employees does Sera Prognostics have?

The company employs 113 workers across the globe.

How can I contact Sera Prognostics?

The official website for the company is www.seraprognostics.com. The company can be reached via phone at 801-990-0520 or via email at peter@capcommpartners.com.

This page (NASDAQ:SERA) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -